| Proposed Ticker: SVLK | 5420 Feltl Road | |
| Exchange: NASDAQ-National Market | Minneapolis, Minnesota 55343 | |
| Industry: Manufacturing | (612) 939-4181 |
| All share information is proposed | ||||
| Type of Shares: | Common Shares | Filing Date: | 5/24/96 | |
| U.S. Shares Filed: | 2,500,000 | Filing Range: | $6.00 - $8.00 | |
| Non-U.S. Shares Filed: | 0 | Offering Amount: | $17,500,000 | |
| Primary Shares: | 2,500,000 | Expenses: | $600,000 | |
| Secondary Shares: | 0 | Shs Out After: | 7,196,257 | |
| Manager | Tier | Phone |
| Natwest Securities Ltd | Lead Manager | (212) 602-4800 |
| John G. Kinnard | Co-manager | (612) 370-2922 |
| Vector Securities International, Inc. | Co-manager | (708) 940-1970 |
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 3/31/96 | 3/31/95 | 3/31/96 | ||
| Revenue: | $1.04 | $0.43 | $0.16 | Assets: | $3.58 |
| Net Income: | -$1.85 | -$1.02 | -$0.43 | Liabilities: | $0.36 |
| EPS: | -$0.41 | -$0.17 | -$0.11 | Equity: | $3.22 |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company manufactures an automated external defibrillator used to treat victims of sudden cardiac arrest. The Company began marketing the VivaLink AED following receipt of 510 (k) marketing clearance by the U.S. Food and Drug Administration in February 1995. The VivaLink incorporates proprietary technologies which make it easy to use, inexpensive and lightweight. In addition, the unit's automatic daily self-testing feature ensures operational readiness. The Company believes that the VivaLink, which is currently used by a broad range of minimally-trained life support ambulance personnel, is the easiest to use AED on the market. To date more than 20 lives have been saved with the VivaLink. Sudden cardiac arrest, which causes more than 350,000 deaths in the United States annually, is caused by disturbances of the heart's electrical signals. As a consequence, blood flow stops, resulting in death if not tested within. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used to expand marketing and distribution capabilities, to introduce new products and for research and development and equipment acquisitions, to repay debt, and for general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.